Medicare AdvantageCoverageMedium impact
MA07.056f, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])
Independence Blue Cross·Dermatology, Oncology, Pharmacy·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
This is a reissue of policy MA07.056f regarding Photodynamic Therapy (PDT) using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA]). The policy was reissued effective March 4, 2026. Billing teams should obtain and review the full policy text to identify any coverage changes, prior authorization requirements, or billing code updates from the previous version.
Action Required
By March 4, 2026: Billing team and providers must access the full policy text at the provided URL to review all coverage criteria, prior authorization requirements, and billing guidelines for PDT using Levulan® Kerastick® or Ameluz®. Update billing system rules, encounter forms, and staff training materials based on the reissued policy requirements. Ensure prior authorization is obtained before service delivery if required. Failure to comply with the updated policy may result in claim denials.